FindTrial
Sign In

Effect of xaban-type anticoagulants on heterotopic ossification in patients undergoing hip replacement after femoral neck fracture

Effect of xaban-type anticoagulants on heterotopic ossification in patients undergoing hip replacement after femoral neck fracture

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400094156
Enrollment
Unknown
Registered
2024-12-17
Start date
2024-10-31
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heterotopic ossification after hip replacement

Interventions

Without xaban-type anticoagulants for adjunctive anticoagulation therapy :None
With xaban-type anticoagulants for adjuvant anticoagulation therapy :None

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients who underwent hip replacement (including total hip replacement and hemihip replacement) due to femoral neck fracture in this clinical center. 2. Aged >= 18 years old, regardless of gender. 3. Able to read and write simplified Chinese, understand and complete the questionnaire, and provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with central nervous system injury, spinal cord injury, burns or destructive injury; 2. Patients with a history of heterotopic ossification; 3. Patients who refused to participate in the study or were lost to follow-up.

Design outcomes

Primary

MeasureTime frame
Heterotopic ossification;—

Countries

China

Contacts

Public ContactSun Ziyang

Shanghai Sixth People's Hospital

cyfan@sjtu.edu.cn+86 189 3017 5149

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026